Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05927428
PHASE2

Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis

Sponsor: BRIM Biotechnology Inc.

View on ClinicalTrials.gov

Summary

The objective of this study is to obtain initial efficacy of BRM424 in patients with Stage 2 and Stage 3 NK and evaluate safety and tolerability.

Official title: An Open-Label, Multi-Center, Phase 2 Dose Ranging Study of BRM424 Ophthalmic Solution in Patients With Neurotrophic Keratitis (NK)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2024-07-31

Completion Date

2025-11-30

Last Updated

2024-10-28

Healthy Volunteers

No

Interventions

DRUG

BRM424 Ophthalmic Solution - Dose1

A topical drop of BRM424 ophthalmic solution.

DRUG

BRM424 Ophthalmic Solution - Dose2

A topical drop of BRM424 ophthalmic solution.

Locations (1)

Wilmington Eye

Leland, North Carolina, United States